• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

预测骨转移性去势抵抗性前列腺癌患者骨相关事件的因素。

Factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer.

作者信息

Klaassen Zachary, Howard Lauren E, de Hoedt Amanda, Amling Christopher L, Aronson William J, Cooperberg Matthew R, Kane Christopher J, Terris Martha K, Freedland Stephen J

机构信息

Department of Surgery, Section of Urology, Medical College of Georgia, Augusta University, Augusta, Georgia.

Department of Surgery, Division of Urology, Durham Veterans Affairs Medical Center, Durham, North Carolina.

出版信息

Cancer. 2017 May 1;123(9):1528-1535. doi: 10.1002/cncr.30505. Epub 2016 Dec 27.

DOI:10.1002/cncr.30505
PMID:28026865
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5562436/
Abstract

BACKGROUND

Skeletal-related events (SREs) are common complications of bone metastatic castration-resistant prostate cancer (mCRPC). To the authors' knowledge, there are limited data regarding which factors predict SREs. The authors identified risk factors for SREs in men with bone mCRPC using characteristics commonly available in the medical record.

METHODS

Data from 454 patients with nonmetastatic CRPC were identified from 2 Veteran Affairs Medical Centers from 2000 through 2013. Among these men, 233 (51%) developed bone metastases during follow-up and represented the study cohort. First occurrence of an SRE was abstracted from the medical records. A stepwise multivariable Cox model was used to select the strongest predictors of time to SRE.

RESULTS

The median age of the patients at the time of diagnosis of bone mCRPC was 75 years (interquartile range, 68-81 years), and there were 153 nonblack patients (66%). During follow-up (median, 7.8 months [interquartile range, 2.9-18.3 months]), 88 patients (38%) had an SRE. On univariable analysis, more recent year of metastasis (hazard ratio [HR], 0.91), prostate-specific antigen doubling time of ≥9 months versus <9 months (HR, 0.50), and bone pain (HR, 3.34) were all found to be associated with SRE risk. On multivariable analysis, year of metastasis (HR, 0.93), biopsy Gleason score of 7 versus ≤6 (HR, 1.74), radiotherapy as the primary localized treatment versus none (HR, 2.33), and bone pain (HR, 3.64) were associated with SRE risk. The area under the curve for a multivariable model based upon these risk factors was 0.744.

CONCLUSIONS

The authors identified several significant predictors of SREs among men with mCRPC. In particular, men with bone pain are at high risk of an SRE. If confirmed, future trials should focus on prolonging life and reducing SRE risk in patients with mCRPC with bone pain. Cancer 2017;123:1528-1535. © 2017 American Cancer Society.

摘要

背景

骨相关事件(SREs)是骨转移去势抵抗性前列腺癌(mCRPC)的常见并发症。据作者所知,关于哪些因素可预测SREs的数据有限。作者利用病历中常见的特征确定了骨mCRPC男性患者发生SREs的危险因素。

方法

从2个退伍军人事务医疗中心收集了2000年至2013年期间454例非转移性CRPC患者的数据。在这些男性患者中,233例(51%)在随访期间发生骨转移,构成研究队列。首次发生SREs的情况从病历中提取。采用逐步多变量Cox模型选择SREs发生时间的最强预测因素。

结果

骨mCRPC诊断时患者的中位年龄为75岁(四分位间距,68 - 81岁),非黑人患者有153例(66%)。在随访期间(中位时间为7.8个月[四分位间距,2.9 - 18.3个月]),88例患者(38%)发生了SREs。单变量分析显示,更近的转移年份(风险比[HR],0.91)、前列腺特异性抗原倍增时间≥9个月与<9个月相比(HR,0.50)以及骨痛(HR,3.34)均与SREs风险相关。多变量分析显示,转移年份(HR,0.93)、活检Gleason评分为7与≤6相比(HR,1.74)、以放疗作为主要局部治疗与未进行放疗相比(HR,2.33)以及骨痛(HR,3.64)与SREs风险相关。基于这些危险因素的多变量模型的曲线下面积为0.744。

结论

作者在mCRPC男性患者中确定了几个SREs的重要预测因素。特别是,有骨痛的男性发生SREs的风险很高。如果得到证实,未来的试验应侧重于延长有骨痛的mCRPC患者的生命并降低其SREs风险。《癌症》2017年;123:1528 - 1535。©2017美国癌症协会。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/309b/5562436/4bf9195e3bef/nihms878707f3a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/309b/5562436/c4ae61d1f59b/nihms878707f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/309b/5562436/1e890684cc42/nihms878707f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/309b/5562436/4bf9195e3bef/nihms878707f3a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/309b/5562436/c4ae61d1f59b/nihms878707f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/309b/5562436/1e890684cc42/nihms878707f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/309b/5562436/4bf9195e3bef/nihms878707f3a.jpg

相似文献

1
Factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer.预测骨转移性去势抵抗性前列腺癌患者骨相关事件的因素。
Cancer. 2017 May 1;123(9):1528-1535. doi: 10.1002/cncr.30505. Epub 2016 Dec 27.
2
Do skeletal-related events predict overall survival in men with metastatic castration-resistant prostate cancer?骨骼相关事件是否可预测转移性去势抵抗性前列腺癌男性患者的总生存期?
Prostate Cancer Prostatic Dis. 2016 Dec;19(4):380-384. doi: 10.1038/pcan.2016.26. Epub 2016 Jul 5.
3
Predictors of skeletal-related events and mortality in men with metastatic, castration-resistant prostate cancer: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.转移性去势抵抗性前列腺癌男性骨骼相关事件和死亡率的预测因素:来自共享平等获得区域癌症医院(SEARCH)数据库的结果。
Cancer. 2019 Nov 15;125(22):4003-4010. doi: 10.1002/cncr.32414. Epub 2019 Aug 7.
4
Race does not predict skeletal-related events and all-cause mortality in men with castration-resistant prostate cancer.种族并不预测去势抵抗性前列腺癌男性的骨骼相关事件和全因死亡率。
Cancer. 2020 Jul 15;126(14):3274-3280. doi: 10.1002/cncr.32933. Epub 2020 May 6.
5
Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy.醋酸阿比特龙联合泼尼松一线治疗转移性去势抵抗性前列腺癌和骨转移患者中,同时使用骨吸收抑制剂与总生存期的相关性。
JAMA Netw Open. 2021 Jul 1;4(7):e2116536. doi: 10.1001/jamanetworkopen.2021.16536.
6
Risk of skeletal related events among elderly prostate cancer patients by site of metastasis at diagnosis.老年前列腺癌患者诊断时转移部位与骨相关事件的风险
Cancer Med. 2016 Nov;5(11):3300-3309. doi: 10.1002/cam4.914. Epub 2016 Oct 11.
7
Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer.骨相关参数是去势抵抗性前列腺癌骨转移患者总生存的主要预后因素。
Eur Urol. 2015 Jul;68(1):42-50. doi: 10.1016/j.eururo.2014.10.001. Epub 2014 Oct 29.
8
Practice patterns and predictors of followup imaging after a negative bone scan in men with castration resistant prostate cancer: results from the SEARCH database.雄激素剥夺治疗后前列腺癌骨扫描阴性患者的随访影像学检查的应用模式和预测因素:SEARCH 数据库研究结果。
J Urol. 2015 Apr;193(4):1232-8. doi: 10.1016/j.juro.2014.11.014. Epub 2014 Nov 13.
9
The Clinical and Economic Impacts of Skeletal-Related Events Among Medicare Enrollees With Prostate Cancer Metastatic to Bone.患有前列腺癌骨转移的医疗保险参保者中骨相关事件的临床和经济影响。
Oncologist. 2016 Mar;21(3):320-6. doi: 10.1634/theoncologist.2015-0327. Epub 2016 Feb 10.
10
Age, Gleason Score, and PSA are important prognostic factors for survival in metastatic castration-resistant prostate cancer. Results of The Uroncor Group (Uro-Oncological Tumors) of the Spanish Society of Radiation Oncology (SEOR).年龄、Gleason 评分和 PSA 是转移性去势抵抗性前列腺癌生存的重要预后因素。西班牙放射肿瘤学会(SEOR)的 Uroncor 小组(泌尿肿瘤学肿瘤)的结果。
Clin Transl Oncol. 2020 Aug;22(8):1378-1389. doi: 10.1007/s12094-019-02274-w. Epub 2020 Jan 27.

引用本文的文献

1
Risk stratification for the prediction of skeletal-related events in patients with castration-resistant prostate cancer with bone metastases.去势抵抗性前列腺癌骨转移患者骨骼相关事件预测的风险分层
PLoS One. 2025 Aug 14;20(8):e0328792. doi: 10.1371/journal.pone.0328792. eCollection 2025.
2
The role of the methyltransferase METTL3 in prostate cancer: a potential therapeutic target.甲基转移酶 METTL3 在前列腺癌中的作用:一个潜在的治疗靶点。
BMC Cancer. 2024 Jan 2;24(1):8. doi: 10.1186/s12885-023-11741-1.
3
Do disease status and race affect the efficacy of zoledronic acid in patients with prostate cancer? A systematic review and meta-analysis of randomized control trials.

本文引用的文献

1
Do skeletal-related events predict overall survival in men with metastatic castration-resistant prostate cancer?骨骼相关事件是否可预测转移性去势抵抗性前列腺癌男性患者的总生存期?
Prostate Cancer Prostatic Dis. 2016 Dec;19(4):380-384. doi: 10.1038/pcan.2016.26. Epub 2016 Jul 5.
2
The Clinical and Economic Impacts of Skeletal-Related Events Among Medicare Enrollees With Prostate Cancer Metastatic to Bone.患有前列腺癌骨转移的医疗保险参保者中骨相关事件的临床和经济影响。
Oncologist. 2016 Mar;21(3):320-6. doi: 10.1634/theoncologist.2015-0327. Epub 2016 Feb 10.
3
Cancer statistics, 2016.
疾病状态和种族是否会影响唑来膦酸治疗前列腺癌患者的疗效?一项随机对照试验的系统评价和荟萃分析。
PLoS One. 2022 Sep 22;17(9):e0275176. doi: 10.1371/journal.pone.0275176. eCollection 2022.
4
Risk factors associated with skeletal-related events following discontinuation of denosumab treatment among patients with bone metastases from solid tumors: A real-world machine learning approach.实体瘤骨转移患者停用地诺单抗治疗后与骨相关事件相关的危险因素:一种真实世界的机器学习方法。
J Bone Oncol. 2022 Mar 17;34:100423. doi: 10.1016/j.jbo.2022.100423. eCollection 2022 Jun.
5
Risk factors of skeletal-related events in patients with bone metastatic castration-resistant prostate cancer undergoing treatment with zoledronate.唑来膦酸治疗骨转移去势抵抗性前列腺癌患者的骨骼相关事件的风险因素。
Support Care Cancer. 2022 Feb;30(2):981-984. doi: 10.1007/s00520-021-06340-4. Epub 2021 Aug 10.
6
Effectiveness of Antalgic Therapies in Patients with Vertebral Bone Metastasis: A Protocol for a Systematic Review and Meta-Analysis.镇痛疗法治疗椎体骨转移患者的效果:系统评价和荟萃分析方案。
Int J Environ Res Public Health. 2021 Apr 10;18(8):3991. doi: 10.3390/ijerph18083991.
7
Safety and Efficacy of Long-Term Zoledronic Acid in Advanced Breast Cancer with Bone Metastasis in South China.唑来膦酸长期治疗中国南方晚期乳腺癌骨转移的安全性与有效性
J Oncol. 2020 Sep 30;2020:5670601. doi: 10.1155/2020/5670601. eCollection 2020.
8
METTL3 enhances cell adhesion through stabilizing integrin β1 mRNA via an m6A-HuR-dependent mechanism in prostatic carcinoma.METTL3通过一种依赖于m6A- HuR的机制稳定整合素β1 mRNA,从而增强前列腺癌细胞的黏附。
Am J Cancer Res. 2020 Mar 1;10(3):1012-1025. eCollection 2020.
9
Predictors of skeletal-related events and mortality in men with metastatic, castration-resistant prostate cancer: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.转移性去势抵抗性前列腺癌男性骨骼相关事件和死亡率的预测因素:来自共享平等获得区域癌症医院(SEARCH)数据库的结果。
Cancer. 2019 Nov 15;125(22):4003-4010. doi: 10.1002/cncr.32414. Epub 2019 Aug 7.
10
Incidence of Skeletal-Related Events in Patients with Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the US.去势抵抗性前列腺癌患者骨相关事件的发生率:美国一项观察性回顾性队列研究
Prostate Cancer. 2019 Jul 9;2019:5971615. doi: 10.1155/2019/5971615. eCollection 2019.
癌症统计数据,2016 年。
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30. doi: 10.3322/caac.21332. Epub 2016 Jan 7.
4
Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer.预测非转移性去势抵抗性前列腺癌骨扫描阳性情况
Prostate Cancer Prostatic Dis. 2015 Dec;18(4):333-7. doi: 10.1038/pcan.2015.25. Epub 2015 May 26.
5
Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer.骨相关参数是去势抵抗性前列腺癌骨转移患者总生存的主要预后因素。
Eur Urol. 2015 Jul;68(1):42-50. doi: 10.1016/j.eururo.2014.10.001. Epub 2014 Oct 29.
6
The burden of skeletal-related events in patients with prostate cancer and bone metastasis.前列腺癌骨转移患者的骨相关事件负担
Urol Oncol. 2015 Jan;33(1):17.e9-17.e18. doi: 10.1016/j.urolonc.2014.09.010. Epub 2014 Oct 30.
7
Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events.地诺单抗预防转移性去势抵抗性前列腺癌骨并发症:骨相关事件与有症状骨事件的比较
Ann Oncol. 2015 Feb;26(2):368-74. doi: 10.1093/annonc/mdu519. Epub 2014 Nov 25.
8
Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial.恩扎卢胺对去势抵抗性前列腺癌男性患者首次骨骼相关事件、疼痛和生活质量的影响:来自随机、III 期 AFFIRM 试验的结果。
Lancet Oncol. 2014 Sep;15(10):1147-56. doi: 10.1016/S1470-2045(14)70303-1. Epub 2014 Aug 4.
9
Skeletal-related events and mortality among older men with advanced prostate cancer.老年晚期前列腺癌男性患者的骨相关事件和死亡率
J Geriatr Oncol. 2014 Jul;5(3):281-9. doi: 10.1016/j.jgo.2014.03.002. Epub 2014 Apr 14.
10
Alpha emitter radium-223 and survival in metastatic prostate cancer.α 粒子发射体镭-223 与转移性前列腺癌的生存。
N Engl J Med. 2013 Jul 18;369(3):213-23. doi: 10.1056/NEJMoa1213755.